PCI upgrades its German cold storage for clinical trials

PCI Pharma Services says that it has doubled the 2-8°C (35.6-46.4°F) capacity at its Berlin facility, as well as adding -20°C (-4°F) and -80°C (-112°F) storage, all in order to “keep pace with global industry trends” in clinical trial logistics and distribution. The additions recently passed regulatory inspections and are fully operational. Further, there are plans to add liquid nitrogen-based storage in a future Phase 2, set to begin in FY 2022.

Brian Keesee, VP and GM, global clinical operations and supply, comments: “These expanded capabilities and breadth of offerings will ensure that our global and mainland EU customers conducting clinical trials, particularly those in the DACH region of Austria, Germany, and Switzerland, have the support of a full-service solution, which the industry prefers, in a prime location with excellent transport hubs.”

PCI completed a new Clinical Center of Excellence at its Berlin location in July 2020, following the acquisition of Bellwyck Pharma Services in early 2020. With the Berlin and Bridgend locations, PCI now services both mainland Europe and mainland UK, which remains an important focus for the company post-Brexit. The Berlin facility is dedicated to secondary packaging, storage of pharmaceutical and biopharmaceutical therapies at all temperature ranges, and distribution.